Compare NX & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NX | GHRS |
|---|---|---|
| Founded | 1927 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 852.1M | 947.2M |
| IPO Year | 2008 | 2021 |
| Metric | NX | GHRS |
|---|---|---|
| Price | $17.68 | $22.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $28.00 | ★ $41.38 |
| AVG Volume (30 Days) | ★ 291.9K | 193.7K |
| Earning Date | 06-04-2026 | 05-01-2026 |
| Dividend Yield | ★ 1.64% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,837,641,000.00 | N/A |
| Revenue This Year | $4.26 | N/A |
| Revenue Next Year | $1.77 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 43.81 | N/A |
| 52 Week Low | $11.04 | $10.96 |
| 52 Week High | $22.90 | $24.66 |
| Indicator | NX | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 42.10 | 61.36 |
| Support Level | $16.61 | $12.65 |
| Resistance Level | $20.24 | $22.88 |
| Average True Range (ATR) | 0.80 | 1.49 |
| MACD | -0.28 | -0.13 |
| Stochastic Oscillator | 38.85 | 58.59 |
Quanex Building Products Corp is a manufacturer of components sold to original equipment manufacturers in the building products industry. It manufactures engineered products like window and door components that include flexible insulating glass spacers, extruded vinyl profiles, window and door screens, solar panel sealants and precision-formed metal and wood products among others. Its four operating segments are North American Fenestration being the key revenue driver, European Fenestration, North American Cabinet Components, and Tyman. Geographically, it derives a majority of revenue from the United States.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.